Rare disease companies develop diagnostics, therapies and research technologies for conditions affecting relatively small patient populations. Their work often focuses on inherited disorders, complex diagnostic pathways and diseases with limited or no existing treatment options.
This category includes companies working on:
Browse 141 UK rare disease companies below.
Full-service CRO specialising in oncology and rare diseases
Simbec-Orion is a full-service CRO providing Phase I to Phase IV clinical trial services, with specialist expertise in oncology, rare and orphan diseases, and clinical pharmacology. Its Merthyr Tydfil campus houses a 58-bed MHRA-accredited Phase I unit, Seirian Laboratories for central pathology and bioanalysis, IMP…
European commercialisation partner for specialty and rare disease medicines
Abacus Medicine Pharmaceuticals is a commercial-stage pharmaceutical company that partners with pharmaceutical and biotechnology developers to launch and commercialise specialty medicines across Europe. It can act as a regional affiliate in selected markets or manage wider European rollouts, covering regulatory,…
Non-surgical drug therapy for spinal cord injury recovery
NeuroSolv Therapeutics is a preclinical-stage biotechnology company developing a non-surgical two-part therapy for spinal cord injury. The proposed mechanism combines enzymatic removal of perineuronal nets on spinal cord neurons with treatment of signal-blocking glial scar tissue, enabling new synaptic connections to…
Stabilised siRNA therapeutics platform targeting cardiovascular gene silencing
Argonaute RNA is a biopharmaceutical company developing small interfering RNA therapeutics for cardiovascular disease. Its siRNA platform uses proprietary chemical stabilisation to enable safe, targeted and temporary gene silencing in specific tissue cells, overcoming delivery and safety barriers that have constrained…
Implantable localised chemotherapy delivery for hard-to-treat solid tumours
CRISM Therapeutics is a clinical-stage drug delivery company developing an implantable biodegradable technology that delivers chemotherapy directly into tumours or surgical margins, reducing the systemic side effects of conventional treatment. Developed with the University of Birmingham, the company's lead programme…
Global population genomics platform for drug target discovery and clinical trials
Omnigen Biodata is a biotechnology company operating the Discover Me platform, a global population health and genomics research programme integrating health and genetic data from participants across multiple countries. The platform generates large-scale biodata resources used by pharmaceutical partners to identify…
Rare disease partnering platform connecting patient groups with drug developers
Aspire Biosciences is a Cambridge-based company accelerating treatment development for rare and unaddressed diseases through its Systematic Serendipity methodology. The company facilitates structured partnerships between rare disease patient organisations and pharmaceutical and biotechnology companies through…
Immunotherapies targeting blood cancer precursor conditions before onset
Athernal Bio is a Cambridge-based biotechnology company developing targeted immunotherapies for high-risk clonal haematopoiesis, a widespread blood stem cell mutation condition that significantly increases the risk of acute myeloid leukaemia and other haematological cancers. The company's pipeline comprises three…
Specialty pharma delivering niche medicines and novel drug delivery technology
Therakind is a specialty pharmaceutical company focused on developing niche medicines for difficult-to-treat patient populations, including children and the elderly. The company has obtained regulatory approvals for three products across the FDA, EMA and MHRA, and has developed a proprietary intranasal dry powder…
Mitochondrial transplantation platform to restore cellular energy and regeneration
Recondria Therapeutics is a developer of a mitochondrial transplantation platform designed to restore cellular energy, accelerate tissue recovery and support regenerative medicine. The company's approach involves isolating healthy mitochondria and delivering them to damaged cells to restore ATP production and cellular…
Medical research charity translating science into treatments and diagnostics
LifeArc is a self-funded UK medical research charity focused on translating early-stage science into treatments and diagnostics for patients with rare diseases and global health challenges. Formerly MRC Technology, the organisation operates its own drug discovery and diagnostics development laboratories in Stevenage…
Cannabinoid medicines, neuroscience and oncology drug development
Jazz Pharmaceuticals is a global biopharmaceutical company focused on medicines for neuroscience and oncology. Its UK operations, centred at Kent Science Park in Sittingbourne, form the heart of its global cannabinoid manufacturing and research activities, inherited through its 2021 acquisition of GW Pharmaceuticals…
National genomics research and NHS whole genome sequencing
Genomics England is a government-owned organisation that partners with the NHS to deliver whole genome sequencing diagnostics and advance genomic medicine in the UK. It operates the National Genomic Research Library, providing approved researchers with access to linked genomic and clinical data to identify the causes…
Specialist CRO for oncology, rare disease, and neurology clinical trials
Evestia Clinical is a global specialist contract research organisation providing full-service and functional clinical trial support to biotech and pharmaceutical companies. The company offers clinical operations, site and project management, regulatory affairs, biostatistics, pharmacovigilance, and medical writing…
Biomarker-driven CRO integrating clinical trials and laboratory sciences
Precision for Medicine is a full-service contract research organisation built around biomarker-driven clinical development. The company integrates clinical trial execution with specialty laboratory services, translational science, data management, and biostatistics to support oncology, rare disease, and cell and gene…
Ion channel drug discovery platform for rare CNS disorders
Autifony Therapeutics is a clinical-stage UK biotech developing small molecule modulators of Kv3 voltage-gated potassium channels for rare genetic CNS disorders. Lead programmes target Fragile X syndrome and rare myoclonic epilepsy syndromes, with preclinical work extending to schizophrenia, hearing loss, and…
Decentralised clinical trial site bringing research to participants
The Virtual Clinical Trial Centre is a clinical research organisation operating a network of flexible, patient-centric trial sites across the UK and Spain. Its decentralised model allows participants to engage in clinical research from home or local sites, addressing the geographic and logistical barriers that limit…
AI platform combining retinal imaging and genomics for inherited eye disease diagnosis
Eye2Gene is an AI-powered precision ophthalmology platform combining retinal imaging with genomic analysis to accelerate diagnosis of inherited retinal diseases. Using a neural network ensemble trained on tens of thousands of multimodal retinal scans, the platform predicts the likely causative gene behind a patient's…
Therapeutics and blood biomarker tests for ALS
Vesalic develops therapeutic and diagnostic approaches for amyotrophic lateral sclerosis (ALS), focusing on the potential role of metabolic dysfunction outside the nervous system. Its preclinical programmes include a treatment candidate designed to address toxic cargo carried by exosomes to motor neurons, alongside a…
Inhaled lentiviral gene therapies for rare respiratory diseases
AlveoGene is a biotechnology company developing inhaled gene therapies for rare respiratory disorders. It uses a lentiviral vector platform engineered to deliver therapeutic genes efficiently to the cells lining the airways and lungs. Its lead programme targets alpha-1 antitrypsin deficiency, an inherited condition…